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In their article in Critical Care, Sponholz et al. [1] com-
pared two devices: the molecular adsorbent recirculating
system (MARS) and single pass albumin dialysis (SPAD).
As Sponholz et al. claim, SPAD is not an effective
method for achieving a significant decrease in the con-
centration of bile acids, creatinine or urea, because a
single SPAD procedure induces a 7.62 % (median) re-
duction in the level of bile acids and an increase in
the concentrations of creatinine and urea by respect-
ively 5.04 % (median) and 4.69 % (median), compared
with pre-dialysis levels [1]. In contrast, our as yet un-
published study demonstrates that SPAD can effect-
ively reduce not only the level of bile acids but also
the concentration of ammonia. Based on our study,
the application of the SPAD method with a dialysate
flow rate of 1000 ml/h for a total of around 10 h re-
duces the level of bile acids by 21.9 % (median) and
ammonia by 16.25 % (median).
A question arises as to the possible causes of such
discrepancies. Since continuous venovenous haemodi-
alysis was performed in both studies, the divergence
cannot be attributed to the technique. In our view,
this divergence is associated with several factors. One
of these factors is the difference in dialysate flow rate.
An albumin dialysate flow rate of 700 ml/h is highly
insufficient. Taking into consideration the results ob-
tained by Sponholz et al., an increase in the albumin
dialysate flow rate to at least 1000 ml/h appears to be
a necessary precondition to ensure effective elimin-
ation of bile acids. Also, the methodology adopted for
the study is questionable. In our opinion, comparing
the effectiveness of urea and creatinine elimination at
radically different dialysate flow rates (SPAD 700 ml/h
vs MARS 2000 ml/h) is unjustified and may lead to
erroneous conclusions, which in fact occurred [1].
Differences in efficacy between the MARS and SPAD
procedures reported in the article in question may
also be related to inappropriately selected haemofilters
in the extracorporeal blood purification systems under
comparison.
Furthermore, Sponholz et al. [1] pointed out metabolic
derangements and electrolyte disturbances, particularly
in SPAD using regional citrate anticoagulation. In our
view, increasing the dialysate flow rate would signifi-
cantly contribute to preventing the irregularities noted
in the study. On the other hand, we believe that the risk
of citrate overdose during liver dialysis, but also during
continuous venovenous haemodialysis, is very low [2–4].
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In our medical centre, we have been successfully per-
forming continuous venovenous haemodialysis proce-
dures with regional citrate anticoagulation in patients
with severe liver dysfunction, sometimes for up to sev-
eral weeks. We have never noted any symptoms of over-
dose apart from end-stage liver failure.
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We appreciate the interest of Piechota and Piechota in
our study. Indeed, SPAD is not a standardised method
either with respect to the albumin concentration in the
dialysate solution or to dialysate flow rates. The rationale
for using dialysis flow rates of 700 ml/h in our study was
based on previously published data on the effective de-
toxification capacity of a 4 % albumin-containing dialysis
solution in vitro [5] and our own experience in critically
ill patients [6]. Moreover, the flow rate of 700 ml/h al-
lows 7 h of treatment duration similar to MARS using
one 5000 ml dialysis bag, resulting in significant changes
in total bilirubin levels. However, neither bile acids nor
creatinine or urea levels could be reduced in this setting.
As discussed extensively, enhancing the dialysis flow
rates and treatment times in SPAD could potentially lead
to higher detoxification capacities accompanied by
higher treatment costs, particularly for higher amounts
of albumin. With respect to treatment times the same
holds true for MARS, when using a new treatment kit.
Furthermore, Piechota and Piechota raised the ques-
tion of metabolic and electrolyte disturbances during
SPAD administration and citrate anticoagulation in our
study. Indeed, we believe that these disturbances were
related to the dialysis flow rate, resulting in relative cit-
rate overdosing, and discussed this issue extensively in our
publication [1]. Increasing the dialysis flow rate could
reduce the risk of citrate overdosing and accumulation.
We demonstrated that regional citrate administration can
be used effectively and safely in the critical care setting
even in patients with severe liver dysfunction [7, 8].
We agree with Piechota and Piechota that the
dialysis haemofilter impacts on efficacy of SPAD.
Reviewing the literature, successful SPAD procedures
were published running with different haemofilters,
including polysulfone filters as used in the current
study (AV1000s polysulfone ultraflux haemofilter;
Fresenius Medical Care, Bad Homburg, Germany).
Thus, the haemofilter is unlikely responsible for our
findings.
To summarise, the SPAD procedure is published to
run at different albumin concentrations, dialysis
modes and flow rates and with different haemofilters.
Currently little is known about the efficacy of SPAD
running in different modalities and no review is
available summarising all of these issues. Our study
thus represents one piece in the puzzle for the
discussion of evaluating and standardising the SPAD
procedure.
Moreover, our study underlines that the often-
performed clinical routine of only assessing the course
of bilirubin levels to evaluate efficacy of extracorporeal
liver support is insufficient.
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